With interest, we read the recent report of a 73-year-old coronavirus disease 2019 (COVID-19) patient with COVID-19-associated aspergillosis (CAPA), developing massive hemoptysis and subsequent refractory cardiac arrest [1]. Post-mortem analysis revealed a massive gaseous embolism, which the clinicians suspected to be the result of a pneumovascular fistula secondary to CAPA. We thank Mombrun and colleagues [1] for their case presentation and would like to substantiate their hypothesis by showing data on a complication with suspected analogous pathomechanism.
Similar to pneumovascular fistula, pneumopleural fistula (PPF) with associated barotrauma secondary to CAPA seems just as reasonable from a pathophysiologic perspective. Barotrauma constitutes a relevant complication among ventilated COVID-19 patients and appears to occur more frequently in COVID-19-associated acute respiratory distress syndrome (ARDS) than in ARDS of other origin [2]. As data on underlying causes are scarce, we analyzed a propensity-matched cohort of ventilated COVID-19 patients from the University Hospital Cologne (UHC) to identify risk factors for PPF. PPF was defined as imaging-confirmed pneumothorax, pneumomediastinum or extensive subcutaneous emphysema. Treatment was performed according to standardized UHC protocols aiming for a Richmond Agitation-Sedation-Scale of 0 to -1 once prone positioning was terminated without regular use of neuromuscular blocking agents. Matching was performed based on a nearest-neighbor matching procedure without replacement with a threshold for absolute standardized mean differences of 0.1 in R, adjusting for suggested risk factors for barotrauma: age, sex, plateau pressure, and tidal volume per predicted body weight at the time of intubation or admission.
Of 143 COVID-19-ARDS-patients with complete biweekly CAPA-screening out of a total of 289 ventilated COVID-19-ARDS-patients at UCH (PPF prevalence 26%), 35 PPF-patients were matched with 35 non-PPF-patients. Regarding complications, a 37% higher incidence of ventilator-associated pneumonia (VAP) (p < 0.001) was observed in PPF-patients. Possible or probable CAPA, defined by the European Confederation of Medical Mycology (ECMM) and the International Society for Human & Animal Mycology (ISHAM) consensus criteria [3], was diagnosed in 40% of PPF-patients compared to 14% in non-PPF-patients (p = 0.016). The odds ratio (OR) for PPF was examined using multiple logistic regression analysis, including the factors initial Acute Physiology And Chronic Health Evaluation II (APACHE-II) score, VAP, CAPA, and duration of ventilation. Only APACHE-II score (OR 1.14, 95% confidence interval (CI) 1.02–1.31, p = 0.015) and CAPA (OR 5.35, 95% CI 1.11–40.8, p = 0.036) were independent predictors for PPF (Fig. 1).
A possible correlation between fungal infections and barotrauma has been recently suggested in an observational study, identifying barotrauma in 68% of patients with COVID-19-associated fungal coinfections [4]. The invasive growth of hyphae destroys the integrity of the airways. This effect is amplified by positive airway pressure needed during mechanical ventilation [5]. These changes could not only predispose patients to develop PPF with associated barotrauma, but may also result in pneumovascular fistula by angioinvasion, as suspected by Mombrun and colleagues [1]. Although histopathological correlates are scarce [6], causal relationships between CAPA and both pneumopleural and pneumovascular fistula seem reasonable from pathophysiologic perspective. Besides limitations due to its retrospective and monocentric design, additional unaccounted confounders may exist despite propensity-matching. However, thorough biweekly CAPA-screening and homogeneous matching groups indicate high levels of representativeness and generalizability.
These findings therefore support the suspected theory and shed new light on CAPA-associated complications, emphasizing the importance of diagnostic strategies to allow for early treatment and contributing to the ongoing debate regarding antifungal prophylaxis in COVID-19-associated ARDS.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- COVID-19:
-
Coronavirus disease 2019
- CAPA:
-
COVID-19-associated pulmonary aspergillosis
- PPF:
-
Pneumopleural fistula
- ARDS:
-
Acute respiratory distress syndrome
- UCH:
-
University Hospital Cologne
- VAP:
-
Ventilator-associated pneumonia
- ECMM:
-
European confederation of medical mycology
- ISHAM:
-
International society for human and animal mycology
- OR:
-
Odds ratio
- APACHE II:
-
Acute physiology and chronic health evaluation II
- CI:
-
Confidence interval
- ICU:
-
Intensive care unit
References
Mombrun M, Marliot C, Jurj A, Ramakers M (2023) Massive gaseous embolism during cardiopulmonary resuscitation for massive hemoptysis in a COVID-19-associated pulmonary aspergillosis. Intensive Care Med. https://doi.org/10.1007/S00134-022-06960-2
McGuinness G, Zhan C, Rosenberg N et al (2020) Increased incidence of barotrauma in patients with COVID-19 on invasive mechanical ventilation. Radiology 297:E252–E262. https://doi.org/10.1148/radiol.2020202352
Koehler P, Bassetti M, Chakrabarti A et al (2021) Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 21:e149–e162. https://doi.org/10.1016/S1473-3099(20)30847-1
Koukaki E, Rovina N, Tzannis K et al (2022) Fungal infections in the ICU during the COVID-19 Era: descriptive and comparative analysis of 178 patients. J Fungi (Basel, Switzerland) 8:881. https://doi.org/10.3390/jof8080881
van de Veerdonk FL, Brüggemann RJM, Vos S et al (2021) COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion. Lancet Respir Med 9:795–802. https://doi.org/10.1016/S2213-2600(21)00138-7
Wauters J, Lamoth F, Rijnders BJA, Calandra T (2021) Invasive pulmonary aspergillosis goes viral again? Am J Respir Crit Care Med 203:275–277. https://doi.org/10.1164/rccm.202012-4413ED
Acknowledgements
The authors would like to acknowledge the hard work and devotion to patient care of all ICU physicians and nurses, enabling this study. Furthermore, we thank Stefan Bauer for the assistance in data collection and Jorge Garcia Borrega, Jannik Stemler, Alexander Shimabukuro-Vornhagen, Dennis Alexander Eichenauer and Matthias Kochanek for their substantial contribution to this study.
Funding
Open Access funding enabled and organized by Projekt DEAL. This study received no funding.
Author information
Authors and Affiliations
Contributions
JHN, PK and BB: conceived the study. JH and JS: conducted the chart reviews of patient and checked for enrollment. JHN, JS, JGS, PK and BB: analyzed and interpreted the data. PK provided figures a-c. JHN and BB: wrote the first draft of the manuscript. JHN, JS, JGS, PK and BB: critically revised the manuscript. All the authors reviewed the final draft of the manuscript and agreed on submitting it to Intensive Care Medicine.
Corresponding author
Ethics declarations
Conflicts of interest
BB received scientific grants and honoraria not related to the submitted manuscript from Noscendo, Novartis, Kite/Gilead, Miltenyi, Pfizer, Roche and Janssen & Janssen. PK reports grants or contracts from German Federal Ministry of Research and Education (BMBF) B-FAST (Bundesweites Forschungsnetz Angewandte Surveillance und Testung) and NAPKON (Nationales Pandemie Kohorten Netz, German National Pandemic Cohort Network) of the Network University Medicine (NUM) and the State of North Rhine-Westphalia; Consulting fees from Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited, Noxxon N.V. and Pfizer Pharma; Honoraria for lectures from Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, BioRad Laboratories Inc., European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, HELIOS Kliniken GmbH, Lahn-Dill-Kliniken GmbH, medupdate GmbH, MedMedia, MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Scilink Comunicación Científica SC and University Hospital and LMU Munich; Participation on an Advisory Board from Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited and Pfizer Pharma; A pending patent currently reviewed at the German Patent and Trade Mark Office; Other non-financial interests from Elsevier, Wiley and Taylor & Francis online outside the submitted work. JHN, JS and JGS declare that they have no competing interests.
Ethics approval and consent to participate
Prior to the start of the study, approval was obtained by the local ethics committee (approval number 20-11729). Given the non-interventional retrospective nature of the study, no informed consent had to be obtained from the included patients.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
134_2023_7040_MOESM3_ESM.pdf
Supplementary file3 Supplemental figure 1: Absolute standardized mean difference. Absolute standardized mean difference before and after propensity score matching using a multivariate logistic regression model for the following suggested risk factors for barotrauma: age, sex, plateau pressure and tidal volume per predicted body weight at the time of intubation or admission. (PDF 5 KB)
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Naendrup, JH., Steinke, J., Grans-Siebel, J. et al. COVID-19-associated pulmonary aspergillosis (CAPA) might be associated with increased risk for pneumopleural fistula. Intensive Care Med 49, 606–608 (2023). https://doi.org/10.1007/s00134-023-07040-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-023-07040-9